When this trial was initiated, there have been no treatments that obviously prolonged survival in this late phase of prostate cancer. The sufferers were randomized to get abiraterone acetate plus prednisone or a placebo plus prednisone each full time. Treatment continued until the cancer progressed, there have been unfavorable reactions, a new treatment was initiated or the patient withdrew from the trial. The study shows individuals taking abiraterone acetate lived about four a few months longer than individuals taking the placebo.Two-sided P values of 0.05 or less were considered to indicate statistical significance. All statistical analyses were performed with the use of SAS software, version 9.3 . Results Study Participants A total of 2971 individuals underwent phenotyping by way of blood testing and imaging, of whom 2924 were included in the analysis of baseline characteristics. Of the 2924 individuals, 161 had lacking covariates and another 347 had incomplete follow-up for non-fatal end points, leaving 2416 participants to be included in the analysis of cardiovascular outcomes.